The company believes it can overcome its challenges, and highlighted strong continued interest from pharma despite a disappointing end to its Merck deal.
The companies plan to develop Thermo's Oncomine Dx Target Test as a companion diagnostic for Blueprint's BLU-667 to identify RET fusions in NSCLC patients.
If approved, the companion test can be used to identify which metastatic breast cancer patients have mutations in BRCA1/2 genes and are likely to respond to Lynparza.
The agency has granted the drug and CDx priority review, which Myriad expects to conclude during its fiscal third-quarter ending March 31, 2018.
Participants shared data from head-to-head assay comparisons, reflected on the advancement of NGS and digital PCR methods, and discussed new standardization projects.
The company is developing a companion diagnostic to identify head and neck cancer patients most likely to benefit from Erbitux.
Gencurix's assay can be used to select which non-small cell lung cancer patients will respond to tyrosine kinase inhibitors.
Patients with PD-L1-expressing gastric or gastroesophageal junction tumors can now be identified for potential treatment with Keytruda using Agilent's assay.
The company's PD-L1 IHC 28-8 pharmDx diagnostic can now be used in cases of urothelial carcinoma and squamous cell carcinoma of the head and neck.
Next year, the company will submit regulatory filings for the drug in two molecularly defined indications and a next-generation sequencing companion diagnostic.
The companies will validate and commercialize the assay as a companion diagnostic to identify best responders to Morphotek's investigational ovarian cancer treatment.
The firm plans to use the funding to expand commercial sales efforts, advance CDx partnerships, build its regulatory infrastructure, and explore new R&D avenues.
The company reported $35.0 million in revenues, driven by higher adoption of its molecular information solutions.
The RealTime PCR instrument identifies AML patients with IDH2 mutations who can be treated with Celgene's Idhifa.
The companies will use HTG EdgeSeq technology to develop NGS-based gene expression profiling assays to support a pharma company's therapeutic development.
As the development of drugs and diagnostics are increasingly beginning to merge, Covance is aiming to dedicate resources to capture market share.
Illumina and Amgen co-developed the test, which will determine whether metastatic colorectal cancer patients will benefit from Vectibix.
Results of a new study offer preliminary evidence that blood tests could select patients for treatment, and track response and resistance.
The test is now CE marked for use in identifying patients with urothelial cancer who are most likely to benefit from Opdivo therapy.
New data now suggests that evaluating PD-L2 levels might better predict response to PD-1 targeting immune-oncology drugs than current tests that only measure PD-L1.
CNN reports that researchers have tied a new variant to opioid addiction risk.
Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.
An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.
In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.